Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
== Contraindications == Sodium hyaluronate has a very low incidence of side effects, however it is contraindicated in people who are sensitive to hyaluronate preparations. If being administered as an intra-articular injection, it should not be given when there are infections or skin disease at the injection site.
-value is much higher. Neutral 187Re does undergo β− decay, with half-life 4.12×1010 years, but Bosch et al., also at Darmstadt, observed that for fully ionized 187Re75+ this is shortened to only 32.9 years. The increase in Q-value of beta decay typically means that additional decay paths to some excited states of the daughter nucleus become energetically allowed. This is exactly what happens in the case of 187Re: in addition to the large increase in decay energy, 187Re75+ is energetically allowed to undergo β− decay to the first-excited state in 187Os75+, a process energetically disallowed for natural 187Re. Similarly, neutral 241Pu undergoes β− decay with a half-life of 14.3 years, but in its fully ionized state the beta-decay half-life of 241Pu94+ decreases to 4.2 days. For comparison, the variation of decay rates of other nuclear processes due to chemical environment is less than 1%. Theoretical examples of nuclides in this category with
==== Territories of the United States ==== Taco Bell operates several stores in Guam. Taco Bell operates one restaurant in the Northern Mariana Islands, located on the island of Saipan. In 2005 Taco Bell started the permitting process to set up a restaurant in American Samoa in Pago Pago. Taco Bell also operates stores in Puerto Rico.
== Function == TRAIL binds to the death receptors DR4 (TRAIL-RI) and DR5 (TRAIL-RII). The process of apoptosis is caspase-8-dependent. Caspase-8 activates downstream effector caspases including procaspase-3, -6, and -7, leading to activation of specific kinases. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation. Application of engineered ligands that have variable affinity for different death (DR4 and DR5) and decoy receptors (DCR1 and DCR2) may allow selective targeting of cancer cells by controlling activation of Type 1/Type 2 pathways of cell death and single cell fluctuations. Luminescent iridium complex-peptide hybrids, which mimic TRAIL, have recently been synthesized in vitro. These artificial TRAIL mimics bind to DR4/DR5 on cancer cells and induce cell death via both apoptosis and necrosis, which makes them a potential candidate for anticancer drug development. Recent studies show that in cancer cells treated with TRAIL, abrupt slowing down of transport at different length scales marks cell death.
==== Peripheral cancers ==== system Xc- function also plays a role in non-neural cancers. Within the gastrointestinal tract, SLC7A11 is upregulated in esophageal, liver, gastric, colorectal, and pancreatic cancers, and inhibition of SLC7A11 has been shown to inhibit tumor progression, likely through induction of ferroptosis. Outside of the gastrointestinal tract, SLC7A11 expression is increased in prostate cancer, bladder cancer, non-small cell lung carcinoma, and melanoma. Inhibition of SLC7A11 in many of these cancers also shows promise in reducing tumor progression.
Sources: en.wikipedia.org
== See also == Iran and weapons of mass destruction Catholic peace traditions Christian pacifism Christianity and violence Just war theory Peace churches Reactions to the 2026 Iran war Regime change efforts in the 2026 Iran war Analysis of the 2026 Iran war Use of religious language and symbolism in the Gaza war
== Symptoms == Desmosis is implicated in disturbed gut motility. Normal peristalsis depends upon the interaction between muscles, nerve cells and tendinous connective tissue. A malfunction of any of these leads to intestinal motility disorders. Patients with desmosis demonstrate chronic constipation.
=== Deep brain stimulation === The support for the use of deep brain stimulation in treatment-resistant depression comes from a handful of case studies, and this treatment is still in a very early investigational stage. In this technique electrodes are implanted in a specific region of the brain, which is then continuously stimulated. A March 2010 systematic review found that "about half the patients did show dramatic improvement" and that adverse events were "generally trivial" given the younger psychiatric patient population than with movements disorders. Deep brain stimulation is available on an experimental basis only in the United States; no systems are approved by the FDA for this use.
Level instrumentation determines the height of liquids by measuring the position of a gas/liquid or liquid/liquid interface within the vessel or tank. Such interfaces include oil/gas, oil/water, condensate/water, glycol/condensate, etc. Local indication (LI) includes sight glasses which show the liquid level directly through a vertical glass tube attached to the vessel/tank. Phase interfaces are maintained at a constant level by level transmitters (LT) transmitting a signal to a level controller (LIC) which compares the measured value with the desired set point. The difference is sent as a signal to a level control valve (LCV) on the liquid outlet from the vessel. As the level rises the controller acts to open the valve to draw off liquid to reduce the level. Similarly as the levels fall the controller acts to close the LCV to reduce outflow of fluid. Some vessels store liquid until it is pumped out. The controller (LIC) acts to start and stop the pump within a specified band. For example, it may start the pump when the level rises to 0.6 m and stop the pump when the level falls to 0.4 m. High and low level alarms (LAH and LAL) warn operating personnel that levels are outside predefined limits. Further deviation (LAHH and LALL) initiates a shutdown either to close emergency shutdown valves (ESDV) on the inlet to the vessel or on the liquid outlet lines. As with high and low pressure instrumentation the shutdown function comprises an independent measurement loop to prevent a common mode failure.
Sources: en.wikipedia.org
Most guidelines recommend combining different preventive strategies. A 2015 Cochrane Review found some evidence that such an approach might help with blood pressure, body mass index and waist circumference. However, there was insufficient evidence to show an effect on mortality or actual cardio-vascular events.
The oldest mention of a university in Wrocław comes from the foundation deed signed on 20 July 1505 for the Generale litterarum Gymnasium in Wrocław by King Vladislaus II of Hungary (Polish: Władysław II Jagiellończyk) of the Polish Jagiellonian dynasty. However, the new academic institution requested by the town council was not built, because the King's deed was rejected by Pope Julius II for political reasons. Also, the numerous wars and opposition from the University of Kraków might have played a role. The first successful founding deed known as the Aurea bulla fundationis Universitatis Wratislaviensis was signed two centuries later, on 1 October 1702, by the Holy Roman Emperor Leopold I of the House of Austria, King of Hungary and Bohemia. The predecessor facilities, which existed since 1638, were converted into Jesuit school, and finally, upon instigation of the Jesuits and with the support of the Silesian Oberamtsrat (Second Secretary) Johannes Adrian von Plencken, donated as a university in 1702 by Emperor Leopold I as a School of Philosophy and Catholic Theology with the designated name Leopoldina. On 15 November 1702, the university opened. Johannes Adrian von Plencken also became chancellor of the university. As a Catholic institute in Protestant Breslau, the new university was an important instrument of the Counter-Reformation in Silesia. After Silesia passed to Prussia, the university lost its ideological character, but remained a religious institution for the education of Catholic clergy in Prussia.
More data on this classification are discoverable at the Expasy metallothionein page.Secondary structure elements have been observed in several MTs SmtA from Syneccochoccus, mammalian MT3, echinoderm SpMTA, fish Notothenia coriiceps MT, crustacean MTH, but until this moment, the content of such structures is considered to be poor in MTs, and its functional influence is not considered. Tertiary structure of MTs is also highly heterogeneous. While vertebrate, echinoderm and crustacean MTs show a bidominial structure with divalent metals as Zn(II) or Cd(II) (the protein is folded so as to bind metals in two functionally independent domains, with a metallic cluster each), yeast and prokaryotic MTs show a monodominial structure (one domain with a single metallic cluster). In yeast, the first 40 residues in the protein wrap around the metal by forming two large parallel loops separated by a deep cleft containing the metal cluster. Although no structural data is available for molluscan, nematoda and Drosophila MTs, it is commonly assumed that the former are bidominial and the latter monodominial. No conclusive data are available for Plant MTs, but two possible structures have been proposed: 1) a bidominial structure similar to that of vertebrate MTs; 2) a codominial structure, in which two Cys-rich domains interact to form a single metallic cluster. Quaternary structure has not been broadly considered for MTs.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.